Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface

Lactobacillus species have been studied for over 30 years in their role as commensal organisms in the human gut. Recently there has been a surge of interest in their abilities to natively and recombinantly stimulate immune activities, and studies have identified strains and novel molecules that conv...

Full description

Saved in:
Bibliographic Details
Main Authors: Joseph R Spangler, Julie C Caruana, Igor L Medintz, Scott A Walper
Format: Article
Language:English
Published: Taylor & Francis Group 2021-04-01
Series:Future Science OA
Subjects:
Online Access:https://www.future-science.com/doi/10.2144/fsoa-2020-0153
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850153094973751296
author Joseph R Spangler
Julie C Caruana
Igor L Medintz
Scott A Walper
author_facet Joseph R Spangler
Julie C Caruana
Igor L Medintz
Scott A Walper
author_sort Joseph R Spangler
collection DOAJ
description Lactobacillus species have been studied for over 30 years in their role as commensal organisms in the human gut. Recently there has been a surge of interest in their abilities to natively and recombinantly stimulate immune activities, and studies have identified strains and novel molecules that convey particular advantages for applications as both immune adjuvants and immunomodulators. In this review, we discuss the recent advances in Lactobacillus-related activity at the gut/microbiota interface, the efforts to probe the boundaries of the direct and indirect therapeutic potential of these bacteria, and highlight the continued interest in harnessing the native capacity for the production of biogenic compounds shown to influence nervous system activity. Taken together, these aspects underscore Lactobacillus species as versatile therapeutic delivery vehicles capable of effector production at the lumenal-mucosal interface, and further establish a foundation of efficacy upon which future engineered strains can expand.
format Article
id doaj-art-3b6a336bf285496b8b885124badaef9f
institution OA Journals
issn 2056-5623
language English
publishDate 2021-04-01
publisher Taylor & Francis Group
record_format Article
series Future Science OA
spelling doaj-art-3b6a336bf285496b8b885124badaef9f2025-08-20T02:25:48ZengTaylor & Francis GroupFuture Science OA2056-56232021-04-017410.2144/fsoa-2020-0153Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interfaceJoseph R Spangler0Julie C Caruana1Igor L Medintz2Scott A Walper31National Research Council Postdoctoral Fellow sited in US Naval Research Laboratory, Code 6900, Center for Bio/Molecular Science & Engineering, 4555 Overlook Ave SW, Washington DC, 20375, USA.2American Society for Engineering Education Postdoctoral Fellow sited in US Naval Research Laboratory, Code 6900, Center for Bio/Molecular Science & Engineering, 4555 Overlook Ave SW, Washington DC, 20375, USA.3US Naval Research Laboratory, Code 6900, Center for Bio/Molecular Science & Engineering, 4555 Overlook Ave SW, Washington DC, 20375, USA3US Naval Research Laboratory, Code 6900, Center for Bio/Molecular Science & Engineering, 4555 Overlook Ave SW, Washington DC, 20375, USALactobacillus species have been studied for over 30 years in their role as commensal organisms in the human gut. Recently there has been a surge of interest in their abilities to natively and recombinantly stimulate immune activities, and studies have identified strains and novel molecules that convey particular advantages for applications as both immune adjuvants and immunomodulators. In this review, we discuss the recent advances in Lactobacillus-related activity at the gut/microbiota interface, the efforts to probe the boundaries of the direct and indirect therapeutic potential of these bacteria, and highlight the continued interest in harnessing the native capacity for the production of biogenic compounds shown to influence nervous system activity. Taken together, these aspects underscore Lactobacillus species as versatile therapeutic delivery vehicles capable of effector production at the lumenal-mucosal interface, and further establish a foundation of efficacy upon which future engineered strains can expand.https://www.future-science.com/doi/10.2144/fsoa-2020-0153cytokine stimulationdelivery vehicleimmunomodulationLactobacillusmicrobiomeprobiotic
spellingShingle Joseph R Spangler
Julie C Caruana
Igor L Medintz
Scott A Walper
Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface
Future Science OA
cytokine stimulation
delivery vehicle
immunomodulation
Lactobacillus
microbiome
probiotic
title Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface
title_full Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface
title_fullStr Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface
title_full_unstemmed Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface
title_short Harnessing the potential of Lactobacillus species for therapeutic delivery at the lumenal-mucosal interface
title_sort harnessing the potential of lactobacillus species for therapeutic delivery at the lumenal mucosal interface
topic cytokine stimulation
delivery vehicle
immunomodulation
Lactobacillus
microbiome
probiotic
url https://www.future-science.com/doi/10.2144/fsoa-2020-0153
work_keys_str_mv AT josephrspangler harnessingthepotentialoflactobacillusspeciesfortherapeuticdeliveryatthelumenalmucosalinterface
AT julieccaruana harnessingthepotentialoflactobacillusspeciesfortherapeuticdeliveryatthelumenalmucosalinterface
AT igorlmedintz harnessingthepotentialoflactobacillusspeciesfortherapeuticdeliveryatthelumenalmucosalinterface
AT scottawalper harnessingthepotentialoflactobacillusspeciesfortherapeuticdeliveryatthelumenalmucosalinterface